{
    "clinical_study": {
        "@rank": "41983", 
        "acronym": "Adjuvant", 
        "arm_group": {
            "arm_group_label": "HER-2 Pulsed Dendritic Cell Vaccine", 
            "arm_group_type": "Experimental", 
            "description": "6 weekly HER-2 pulsed dendritic cell vaccines followed by 3 booster vaccines once every 3 months. Each dose will consist of between 1.0-2.0 x 107 cells and will be injected into 1-2 different normal groin lymph nodes or axillary nodes."
        }, 
        "brief_summary": {
            "textblock": "This trial will be determine the safety and immunogenicity of HER-2 pulsed DC1 vaccine in\n      high risk HER-2 high and intermediate expression breast cancers. Subjects will have HER-2\n      driven IBC at least Stage IIIA with N2 following chemotherapy with/without trastuzumab or\n      recurrence exclusive of new primary tumor but rendered NED. Mammogram, laboratory studies,\n      CT, and leukapheresis will be performed, in addition to vaccine administration."
        }, 
        "brief_title": "HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer", 
        "completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Recurrence"
            ]
        }, 
        "detailed_description": {
            "textblock": "Dendritic cell cancer vaccines combined with chemotherapy may increase complete responses\n      giving breast cancer specific immune cells greater opportunity to function while the immune\n      repertoire is being shifted by chemotherapy to anti-breast cancer response and offer the\n      chance to test secondary prevention of breast cancer in high risk settings. Subjects with\n      HER-2 driven IBC at least Stage IIIA with N2 (4 positive nodes) following chemotherapy with\n      or without trastuzumab or those with recurrence exclusive of new primary tumor but rendered\n      NED will be undergo mammograms, laboratory studies, and leukapheresis. Vaccines will be\n      manufactured using subjects leukapheresis product, which will be administered in the\n      Clinical Research Center 1 Dulles Building weekly for 6 weeks. Three booster vaccines will\n      be administered at 3 month intervals following the initial induction vaccines. Immune\n      analysis will be done after subject receives all induction vaccines and again after they\n      receive all booster vaccines."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Women over Age 18 years.\n\n          -  Subjects with Invasive Breast Cancer at least Stage IIIA greater than or equal to N2\n             (4 positive nodes) or have recurrent metastatic breast cancer rendered NED by any\n             means that are classic HER-2 3+ 30%, 2+ IHC and FISH positive or HER-2 2+ FISH\n             negative verified by the Department of Pathology at the Hospital of the University of\n             Pennsylvania that have completed chemotherapy and/or trastuzumab and are within 1\n             year from there last treatment and have no evidence of disease.\n\n          -  Patients deemed to require anti-estrogen therapy for treatment of their breast cancer\n             can continue anti-estrogen therapy during vaccinations\n\n          -  Women of childbearing age with a negative pregnancy test documented prior to\n             enrollment.\n\n          -  Subjects with ECOG Performance Status Score of 0 or 1 (Appendix D).\n\n          -  Subjects willing to use birth control if necessary\n\n          -  Subjects who have voluntarily signed a written Informed Consent in accordance with\n             institutional policies after its contents have been fully explained to them.\n\n        Exclusion Criteria:\n\n          -  Pregnant or lactating females.\n\n          -  Subjects with positive HIV or hepatitis C at baseline by report.\n\n          -  Subjects with coagulopathies, including thrombocytopenia with platelet count less\n             than 75,000, INR greater than 1.5 and partial thromboplastin time greater than 50 sec\n\n          -  Subjects with major cardiac illness MUGA less than 50% EF.\n\n          -  Subjects with pre-existing medical illnesses or medications which might interfere\n             with the study as determined by PI."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02063724", 
            "org_study_id": "818532", 
            "secondary_id": "25113"
        }, 
        "intervention": {
            "arm_group_label": "HER-2 Pulsed Dendritic Cell Vaccine", 
            "description": "6 weekly HER-2 pulsed dendritic cell vaccines followed by 3 booster vaccines once every 3 months. Each dose will consist of between 1.0-2.0 x 107 cells and will be injected into 1-2 different normal groin lymph nodes or axillary nodes.", 
            "intervention_name": "HER-2 pulsed Dendritic Cell Vaccine", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Invasive Breast Cancer", 
            "Breast Cancer", 
            "Immunotherapy", 
            "Vaccine", 
            "Dendritic Cell"
        ], 
        "lastchanged_date": "February 12, 2014", 
        "link": {
            "url": "http://www.uphs.upenn.edu/surgery/Clinical/faculty/czerniecki_brian.html"
        }, 
        "location": {
            "contact": {
                "email": "jeanne.kobilnyk@uphs.upenn.edu", 
                "last_name": "Jeanne Kobilnyk, MBE", 
                "phone": "215-349-8399"
            }, 
            "facility": {
                "address": {
                    "city": "Philadelphia", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "19104"
                }, 
                "name": "Hospital of the University of Pennsylvania"
            }, 
            "investigator": [
                {
                    "last_name": "Brian J Czerniecki, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Angela DeMichele, MD, MSCE", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Robert Roses, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Carla Fisher, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Kevin Fox, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Susan Domchek, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Keerthi Gogineni, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Bonnie Ky, MD, MSCE", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Susan Weinstein, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Paul Zhang, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Rosemarie Mick, MS", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Pilot Phase I HER-2 Pulsed DC Vaccine to Prevent Recurrence for Patients With HER-2 Driven High Risk Invasive Breast Cancer", 
        "overall_contact": {
            "email": "jeanne.kobilnyk@uphs.upenn.edu", 
            "last_name": "Jeanne Kobilnyk, MBE", 
            "phone": "215-349-8399"
        }, 
        "overall_official": {
            "affiliation": "University of Pennsylvania", 
            "last_name": "Brian J Czerniecki, M.D., Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Blood pressure will be obtained just prior to the vaccination then every 15 minutes for the first hour after the dose is given in order to identify and measure any chnge from baseline.", 
                "measure": "Change in Blood Pressure", 
                "safety_issue": "Yes", 
                "time_frame": "15, 30, 45, & 60 minutes post vaccine"
            }, 
            {
                "description": "Temperature will be obtained just prior to the vaccination then every 15 minutes for the first hour after the dose is given in order to identify and measure any chnge from baseline.", 
                "measure": "Change in Temperature", 
                "safety_issue": "Yes", 
                "time_frame": "15, 30, 45, & 60 minutes post vaccine"
            }, 
            {
                "description": "Pulse will be obtained just prior to the vaccination then every 15 minutes for the first hour after the dose is given in order to identify and measure any chnge from baseline.", 
                "measure": "Change in Pulse", 
                "safety_issue": "Yes", 
                "time_frame": "15, 30, 45, & 60 minutes post vaccine"
            }
        ], 
        "reference": [
            {
                "PMID": "17638860", 
                "citation": "Czerniecki BJ, Roses RE, Koski GK. Development of vaccines for high-risk ductal carcinoma in situ of the breast. Cancer Res. 2007 Jul 15;67(14):6531-4. Review."
            }, 
            {
                "PMID": "17293384", 
                "citation": "Czerniecki BJ, Koski GK, Koldovsky U, Xu S, Cohen PA, Mick R, Nisenbaum H, Pasha T, Xu M, Fox KR, Weinstein S, Orel SG, Vonderheide R, Coukos G, DeMichele A, Araujo L, Spitz FR, Rosen M, Levine BL, June C, Zhang PJ. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res. 2007 Feb 15;67(4):1842-52. Epub 2007 Feb 9."
            }, 
            {
                "PMID": "22130160", 
                "citation": "Koski GK, Koldovsky U, Xu S, Mick R, Sharma A, Fitzpatrick E, Weinstein S, Nisenbaum H, Levine BL, Fox K, Zhang P, Czerniecki BJ. A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer. J Immunother. 2012 Jan;35(1):54-65. doi: 10.1097/CJI.0b013e318235f512."
            }, 
            {
                "PMID": "22252842", 
                "citation": "Sharma A, Koldovsky U, Xu S, Mick R, Roses R, Fitzpatrick E, Weinstein S, Nisenbaum H, Levine BL, Fox K, Zhang P, Koski G, Czerniecki BJ. HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ. Cancer. 2012 Sep 1;118(17):4354-62. doi: 10.1002/cncr.26734. Epub 2012 Jan 17."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02063724"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Pennsylvania", 
            "investigator_full_name": "Brian Czerniecki", 
            "investigator_title": "Harrington/Rhoades Professor of Surgery", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Subjects will undergo leukapheresis after completion of 6 vaccines and 3 boost vaccines for the purpose of obtaining lymphocytes and monocytes for in vitro immunologic testing.", 
                "measure": "Immune Response", 
                "safety_issue": "No", 
                "time_frame": "6-8 weeks, 1 year"
            }, 
            {
                "description": "All subjects will have a post-vaccine bilateral mammogram to evaluate response to vaccination. Mammograms will be performed within two weeks after the 6th vaccination.", 
                "measure": "Mammogram", 
                "safety_issue": "No", 
                "time_frame": "6-8 weeks"
            }
        ], 
        "source": "University of Pennsylvania", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Pennsylvania", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}